Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    VolitionRx

    MCap

    USD76m

    Last close

    USD0.81

    ▲ 0.14 (20.90%)

    Canyon Resources

    MCap

    AUD262m

    Last close

    AUD0.19

    ▲ 0.02 (12.12%)

    Immix Biopharma

    MCap

    USD51m

    Last close

    USD1.82

    ▲ 0.12 (7.06%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Meet Kazia’s management team and hear about paxalisib, Kazia’s lead programme

Meet Kazia’s management team and hear about paxalisib, Kazia’s lead programme

Kazia Therapeutics — 9 videos in collection

More on this equity

Kazia Therapeutics (KZIA) is an oncology-focused drug development company. Its drug candidates are designed to treat cancers which are poorly served by existing therapies.

In this video, James Garner, CEO, introduces Kazia’s expanding US management team: chief medical officer, John Friend, and chief financial officer, Karen Krumeich. John and Karen highlight their experience and what interested them about Kazia. As part of a three-episode Edison TV series, the team also discusses Kazia’s lead asset, paxalisib, a highly potent, small molecule, brain-penetrant inhibitor of PI3K/mTOR, and when we can expect final data from the ongoing Phase III study. Stay tuned for the next video, which focuses on paxalisib beyond glioblastoma.

< Previous
Next >

You may also be interested in these:

Healthcare

Kazia Therapeutics webinar - Combating childhood brain cancer

Healthcare

EVT801, Kazia’s second programme, and capital markets

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free